Chengdu Olymvax Biopharmaceuticals Inc. (SHA:688319)
China flag China · Delayed Price · Currency is CNY
25.08
-0.61 (-2.37%)
Nov 17, 2026, 3:00 PM CST

SHA:688319 Balance Sheet

Millions CNY. Fiscal year is Jan - Dec.

Assets

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Equivalents
158.87246.61224.16362.07269.23254.37
Trading Asset Securities
2.62.617.5090200
Cash & Short-Term Investments
161.47249.21241.66362.07359.23454.37
Cash Growth
-25.68%3.12%-33.26%0.79%-20.94%298.63%
Accounts Receivable
811.17655.97570.35491.55491.69342.52
Other Receivables
1.552.5811.13.781.1
Receivables
812.72658.55571.35492.65495.48343.62
Inventory
57.0262.3885.6872.1278.5274.5
Prepaid Expenses
-1.05-000.06
Other Current Assets
32.0825.149.454.352.662.42
Total Current Assets
1,063996.33908.14931.19935.89874.98
Property, Plant & Equipment
606.64630.67572.3425.87378.35259.27
Other Intangible Assets
18.8816.916.3316.8217.5113.78
Long-Term Deferred Tax Assets
33.5124.9118.2114.079.567.11
Long-Term Deferred Charges
399.4354.04291.5195.76132.3134.93
Other Long-Term Assets
0.740.220.5628.895.2421.82
Total Assets
2,1222,0231,8071,6131,4791,212

Liabilities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Accounts Payable
138.38153.0786.2940.0680.6834.28
Accrued Expenses
0.18465.14368.06346.13321.65251.98
Short-Term Debt
903024.224.28535
Current Portion of Long-Term Debt
92.2368.8287.4231.6910-
Current Portion of Leases
-3.24----
Current Income Taxes Payable
12.01-9.443.749.464.03
Current Unearned Revenue
0.350.990.513.626.717.5
Other Current Liabilities
486.6115.8319.6726.7911.738.88
Total Current Liabilities
819.76737.07595.59476.22525.23341.66
Long-Term Debt
322.94323.72249.53177.2929.99-
Long-Term Leases
3.757.260.644.439.043.25
Long-Term Unearned Revenue
43.1729.1624.7919.9820.1118.67
Long-Term Deferred Tax Liabilities
14.468.392.462.722.562.3
Other Long-Term Liabilities
22.9813.480.531.210.091.33
Total Liabilities
1,2271,119873.54681.84587.02367.22

Shareholders' Equity

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Common Stock
405.41405.71405.93406.16405.27405.27
Additional Paid-In Capital
556.21560.58606605.75580.95570.56
Retained Earnings
-66.23-59.44-81.7-87.04-104.59-131.17
Treasury Stock
--3.17-5.56-7.96--
Total Common Equity
895.4903.68924.68916.91881.63844.66
Minority Interest
-0.38.8213.8610.22-
Shareholders' Equity
895.4903.98933.5930.77891.85844.66
Total Liabilities & Equity
2,1222,0231,8071,6131,4791,212

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Total Debt
508.92433.03361.79237.61134.0338.25
Net Cash (Debt)
-347.45-183.82-120.13124.47225.2416.11
Net Cash Growth
----44.73%-45.88%381.08%
Net Cash Per Share
-0.86-0.45-0.300.310.561.08
Filing Date Shares Outstanding
403.91405.71405.93406.16405.27405.27
Total Common Shares Outstanding
403.91405.71405.93406.16405.27405.27
Working Capital
243.52259.26312.55454.97410.67533.31
Book Value Per Share
2.222.232.282.262.182.08
Tangible Book Value
876.52886.78908.35900.08864.11830.88
Tangible Book Value Per Share
2.172.192.242.222.132.05
Buildings
-224.69224.6996.22103.17103.17
Machinery
-383.4318.26299.39261.88245.29
Construction In Progress
-226.26211.27181.35135.4911.63